BASIC AND CLINICAL STUDIES ON T-2588 TREATMENT IN URINARY TRACT INFECTIONS
スポンサーリンク
概要
- 論文の詳細を見る
Basic and clinical studies were carried out on T-2588, a new oral cephem antibiotic. The results of those studies were as follows.<BR>1) Antibacterial activity (MIC): The MICs of T-2525, CCL, CMZ, LMOX, ABPC and NFLX were determined for 11 species of bacteria, that is, <I>E. coli, K. pneumoniae, P.mirabilis</I>, Indole positive <I>Proteus</I> spp., <I>S. marcescens, Enterobacter</I> spp., <I>Citrobacter</I> spp., <I>P.aeruginosa</I>, NF-GNR, <I>E. faecalis</I> and <I>S. epidermidis</I>, isolated in the field of urology by our department. In the case of <I>P.mirabilis</I>, the MIC distributions of T-2525 showed less than 0. 39 μg/ml about all strains and the activity was most favorable in these 6 antibiotics. Against <I>E. coli</I> and <I>K. pneumoniae</I>, MICs of T-2525 were distributed less than 0.78 μg/ml about almost strains, and T-2525 was less active than NFLX and LMOX. Against Indole positive <I>Proteus</I> spp. and <I>Citrobacter</I> spp., MIC of T-2525 were distributed widely, but 82.0% and 61.3% of which were distributed less than 0.78 μg/rill respectively. In the case of <I>S. epidermidis</I>, the MICs of T-2525 were determined, 68% of which was distributed less than 6.25 μg/ml, and the activity was comparatively favorable. Against <I>S. marcescens</I>, 56% of the MICs were distributed more than 25 μg/ml, and low receptivity was indicated. <I>P.aeruginosa</I>, NF-GNR and <I>E. faecalis</I> were resistant to T-2525.<BR>2) Clinical results: In 22 patients diagnosed as acute uncomplicated cystitis, T-2588 was given for 3 to 10 days at a daily dose of 100 mg (one time) to 200 mg (2 times), and the efficacy rate was 100%. For a study of relapse of the cystitis, after 7 days treatment of T-2588 and 7 days periods after administration almost all patients except for 1 patient were prevented the relapse of the cystitis. In 16 patients diagnosed as complicated urinary tract infections, the efficacy rate was 73% by the criteria-of UTI committee and 79% by the judgement of principal investigator.<BR>There were not subjective side effect except for gastric pain and mild diarrhea in 1 case, mild diarrhea in 1 case, hypernatremia in 1 case and abdominal discomfort in 1 case, and on which cases, administration of T-2588 was not suspended. No abnormal clinical laboratory data by administration of T-2588 except for transient elevation of GOT and GPT was noted.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.